Advertisement

Topics

Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017

16:15 EST 13 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
FDA has lifted the clinical hold from both Phase 1 trials of UCART123 in acute myeloid leukemia (AML) and in blastic plasmacytoid dendritic cell neoplasm (BPDCN) Preliminary results of the first-in-hu...

Other Sources for this Article

Cellectis
Media:
Jennifer Moore, 917-580-1088
VP of Communications
media@cellectis.com
or
Caitlin Kasunich, 212-896-1241
KCSA Strategic Communications
ckasunich@kcsa.com
or
IR:
Simon Harnest, 646-385-9008
VP of Corporate Strategy and Finance
simon.harnest@cellectis.com

NEXT ARTICLE

More From BioPortfolio on "Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017"

Advertisement
Quick Search
Advertisement
Advertisement